Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer

Strategies for successful primary treatment of HER2-positive breast cancer include use of the HER2 inhibitors trastuzumab or lapatinib in combination with standard chemotherapy. While successful, many patients develop resistance to these HER2 inhibitors indicating an unmet need. Consequently, curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Phelps-Polirer, Kendall, Abt, Melissa A., Smith, Danzell, Yeh, Elizabeth S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821489/
https://www.ncbi.nlm.nih.gov/pubmed/27045589
http://dx.doi.org/10.1371/journal.pone.0153025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821489/
https://www.ncbi.nlm.nih.gov/pubmed/27045589
http://dx.doi.org/10.1371/journal.pone.0153025

Ejemplares similares